Dibenzothiophene-d₈

Cat. No.: HY-B0973S: Data Sheet Handling Instructions
FAQs
Technical Support

Dibenzothiophene-d₈ is the deuterium labeled Dibenzothiophene (HY-B0973). Dibenzothiophene is an orally active and a noncompetitive CYP1A inhibitor. Dibenzothiophene inhibits CYP1A-mediated EROD activity with K_m of 0.592 μM. Dibenzothiophene interacts with the AHR pathway. Dibenzothiophene enhances the embryotoxicity of β-naphthoflavone (HY-114740). Dibenzothiophene shows acute toxicity in mice. Dibenzothiophene is mainly used for the study of the mechanism of developmental toxicity in organisms.

For research use only. We do not sell to patients.

Dibenzothiophene-d<sub>8</sub> Chemical Structure

Dibenzothiophene-d₈ Chemical Structure

CAS No. : 33262-29-2

Size	Price	Stock	Quantity
1 mg		Get quote	Estimated Time of Arrival: December 31
5 mg		Get quote 2-4 weeks 2-4 weeks 2-4 weeks	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Dibenzothiophene-d₈:

Dibenzothiophene In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

Biological Activity
Purity & Documentation
References
Customer Review

Description	Dibenzothiophene-d₈ is the deuterium labeled Dibenzothiophene (HY-B0973). Dibenzothiophene is an orally active and a noncompetitive CYP1A inhibitor. Dibenzothiophene inhibits CYP1A-mediated EROD activity with K_m of 0.592 μM. Dibenzothiophene interacts with the AHR pathway. Dibenzothiophene enhances the embryotoxicity of β-naphthoflavone (HY-114740). Dibenzothiophene shows acute toxicity in mice. Dibenzothiophene is mainly used for the study of the mechanism of developmental toxicity in organisms^[1]^[2].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Dibenzothiophene-d₈ Related Antibodies
Molecular Weight	192.31
Formula	C₁₂D₈S
CAS No.	33262-29-2
Unlabeled CAS	132-65-0
SMILES	[2H]C1=C2C3=C([2H])C([2H])=C([2H])C([2H])=C3SC2=C([2H])C([2H])=C1[2H]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (273 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]